You Can See Everything chronicles the final weeks before disgraced entrepreneur Elizabeth Holmes went to prison in 2023. Since its US release last week, the film has thrust Holmes and her failed blood-testing start-up, Theranos, back into the spotlight. For the biotechnology industry, however, the spectre of Theranos never went away. More than a decade after the company's spectacular collapse, a new generation of diagnostics firms still grapples with the fallout. During the 2010s, Theranos said that its device could run hundreds of tests on only a few drops of blood, drastically reducing the amount of fluid needed for routine diagnostics. The company's success soared as investors backed the technology, but US federal juries later ruled that Theranos had misled those financial supporters about its device's capabilities, and two of its executives, including Holmes, were sentenced to more than a decade in prison. Today, health-tech companies are still developing devices similar to the...
learn more
